First Month on GLP-1: A Week-by-Week Guide

The first month on a GLP-1 medication is mostly about adjustment, not results. Starting doses are intentionally low — they exist to let your digestive system adapt, not to drive weight loss. Understanding that upfront prevents a lot of early discouragement, because the scale is rarely where the action is in these opening weeks. The action is in your appetite, your relationship to food, and how your gut responds to a hormone signal it is not used to receiving at this strength.

This guide walks through the first four weeks in the order most people experience them, then covers the eating adjustments that make those weeks easier and the difference between symptoms that are expected and symptoms that warrant a call. None of it is a substitute for the instructions your own prescriber gives you. It is a map of the typical terrain, drawn from the science of how these drugs work and from the large trials that established them. For the fuller mechanism behind everything here, the complete guide to GLP-1 medications and weight science is the place to start, and the broader collection of first-month and beginner topics lives in the GLP-1 science cluster.

Why the starting dose is so low

The single most important thing to understand about week one is that you are not starting on a weight-loss dose. Semaglutide typically begins at 0.25 mg weekly and tirzepatide at 2.5 mg weekly, and neither of these is the dose that produced the headline results in the trials. They are tolerance-building doses, and the slow climb upward from them — titration — is the whole point of the early schedule.

The reason is mechanical. GLP-1 receptor agonists slow the rate at which your stomach empties and act on appetite circuits in the brain. As Daniel Drucker's 2018 review in Cell Metabolism describes, native GLP-1 is a post-meal hormone that simultaneously enhances insulin release, slows gastric emptying, and signals satiety; the medications are engineered to do the same thing but last for days rather than minutes. Delivering that signal all at once, at full strength, to a gut that has never experienced it is what produces severe nausea. Starting low and stepping up gives the gastrointestinal system time to adapt at each level before the next increase. In both the STEP 1 trial of semaglutide (Wilding and colleagues, 2021) and the SURMOUNT-1 trial of tirzepatide (Jastreboff and colleagues, 2022), participants were titrated gradually for exactly this reason, and side effects were predominantly mild to moderate and led only a small minority to stop.

Skipping or rushing titration is one of the most common reasons people experience side effects bad enough to quit. The schedule is built around your gut's adaptation, not your impatience. If you want the full ramp laid out, see the semaglutide dosing schedule.

Week 1: The quiet start

Most people feel very little in the first few days. The starting dose of semaglutide (0.25 mg) or tirzepatide (2.5 mg) is a tolerance-building dose, not a therapeutic one. You may notice you feel full slightly faster at dinner, or that you think about food a little less. You may also notice nothing at all — that is completely normal and not a sign the medication isn't working.

A small number of people do get nausea in the first week, usually mild and usually in the day or two following the injection. If it appears, it tends to be the gut registering slowed emptying for the first time. More often, week one is uneventful, and the temptation that follows is the dangerous part: feeling nothing, some people conclude the dose is too weak and consider increasing it early.

If you feel no appetite change in week one, do not increase your dose on your own. The titration schedule is designed around tolerance, not impatience.

If you have not already, this is also the week to get your logistics right — injection technique, day-of-week routine, and stocking your kitchen with the foods that make the next three weeks easier. A practical pre-start list is in the GLP-1 checklist before starting.

Week 2: Food noise starts to fade

By the second week, many people describe a reduction in "food noise" — the background mental chatter about snacks and the next meal. Meals feel smaller because they are satisfying sooner. This is a direct effect of how GLP-1 acts on the brain's appetite pathways, and it is the change most people find genuinely surprising.

The science behind it is well characterised. Liselotte van Bloemendaal and colleagues showed in 2014, using functional MRI, that GLP-1 receptor activation reduced activation in reward-related brain regions — the insula, amygdala, and orbitofrontal cortex — specifically in response to images of food. The effect was selective: GLP-1 was not dampening pleasure in general, only turning down the reward system's reactivity to food cues. That is the neurobiology of food noise quieting. The constant pull toward the kitchen, the difficulty leaving food on the plate, the 11am preoccupation with lunch — these soften because the circuitry that generates them has become less reactive. Many people report this as more meaningful than any number on the scale, because it frees up mental space that food management had occupied for years.

Week two is also when mild nausea is most common for those who get it, usually in the day or two after an injection. The mechanism is the same slowed gastric emptying that produces the fullness — the appetite tool overshooting slightly. A few practical adjustments make a large difference:

• Eat slowly and stop at the first sign of fullness — your old portion sizes will now overshoot.
• Front-load protein and water early in the day.
• Greasy, heavy meals are the most common nausea trigger in this window.

If nausea is more than a background nuisance, the dedicated guide to managing nausea on GLP-1 ranks the interventions by how well they actually work.

Week 3-4: Finding your rhythm

By the end of the first month you usually have a clear sense of how the medication feels in your body. Appetite suppression is more consistent, side effects (if any) are predictable, and depending on your schedule you may be approaching or have already had your first dose increase. Weight on the scale may have moved a few pounds — or barely at all. Both outcomes are within the normal range this early.

This is worth dwelling on, because the scale is the single biggest source of early discouragement and the least informative metric this soon. Early weight changes are dominated by water shifts and day-to-day noise, and at a tolerance-building dose the appetite effect is still ramping. The STEP 1 and SURMOUNT-1 trials produced their large average losses — roughly 15% of body weight with semaglutide and up to about 21% with high-dose tirzepatide — over 68 to 72 weeks of treatment at full doses, not in month one. What you are looking for in week four is not pounds lost but signs the medication is engaging: smaller portions feeling natural, less snacking, quieter food noise, manageable side effects. Those are the leading indicators. The pounds follow later.

If a dose increase lands in this window and brings a fresh wave of nausea, that is expected — each step up reintroduces the adaptation period in miniature. It usually settles within a week or so, the same way the starting dose did.

Eating adjustments that make the month easier

Almost every comfortable first month comes down to eating with slowed digestion rather than against it. The stomach now empties slowly, so the volume that used to feel normal arrives against a stomach that is not yet empty — which is exactly how the satiety effect works, and exactly why large or fatty meals sit heavily and trigger nausea.

Three adjustments do most of the work. Eat smaller meals, more slowly, and stop at "no longer hungry" rather than "full." Cut back on fatty and fried foods, which empty especially slowly and are the most reliable nausea trigger in the early weeks. And hydrate between meals rather than during them, since large volumes of fluid with food add to stomach volume. A fuller framework for the plate — what to prioritise and what to scale back — is in what to eat on GLP-1.

One macronutrient deserves special attention: protein. When appetite drops sharply, protein is usually the first thing to fall off the plate, because protein-rich foods take effort to prepare and chew and feel filling when you are already not hungry. That matters because inadequate protein during weight loss accelerates the loss of lean muscle alongside fat. The hormonal biology underlying why the body defends its weight at all — elevated hunger signalling, including the pre-meal ghrelin rise that Cummings and colleagues mapped in 2001, and the reduced energy expenditure after weight loss documented by Priya Sumithran's team in 2011 and by Rudolph Leibel's group as far back as 1995 — is the reason muscle is worth protecting deliberately. Treat a daily protein floor as non-negotiable even on low-appetite days, and front-load it early when your appetite is still present.

What's normal and what isn't

The side-effect profile of GLP-1 medications follows directly from their mechanism, which makes most of it predictable. The common effects are gastrointestinal: nausea, occasional vomiting, diarrhoea, constipation, reflux, and a general early fullness. These are expected, generally mild to moderate, and tend to settle substantially over the first weeks as the body adapts. Mild fatigue and reduced appetite are likewise within the normal range. None of these, on their own and at a manageable level, mean something is wrong — they mean the drug is doing what it does.

It is also worth noting what these medications typically do not cause, because the contrast with older appetite suppressants reassures people who expect it. They are not stimulants, so they do not produce a racing heart, jitteriness, or the revved-up feeling that defined earlier diet drugs. The appetite reduction arrives quietly, as diminished interest in food. Its absence of drama is normal, not a sign the medication is inert.

What is not in the expected range — and what warrants prompt contact with your prescriber — is a smaller, more specific list:

• Severe or persistent vomiting, or being unable to keep fluids down.
• Signs of dehydration — dizziness, very dark urine, a racing heart on standing.
• Severe abdominal pain, especially pain that radiates to your back, which can be a sign of pancreatitis.
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes, which can signal gallbladder problems.
• Any symptom that simply feels alarming or out of proportion.

These are uncommon, but they are the reason GLP-1 drugs are prescription medications evaluated by a clinician rather than products taken casually. The much larger category — manageable nausea, predictable fullness, an unmoving scale — is the ordinary texture of a normal first month. For the expected arc of symptoms over time, including when each tends to appear and fade, the GLP-1 side effects timeline lays it out week by week.

The mistakes worth avoiding

• Under-eating. A suppressed appetite makes it easy to drift to 800–1000 calories a day. That accelerates muscle loss and tanks your energy. Aim to eat real, structured meals even when you're not hungry.
• Skipping protein. Protein is the single most important macro on a GLP-1. Set a floor and hit it daily, even on low-appetite days, front-loading it earlier when appetite is still present.
• Chasing the scale weekly. Early weight changes are mostly water and noise. Judge progress in 4-week blocks, and judge the first month by appetite and tolerability rather than pounds.
• Self-escalating the dose. Feeling little on a starting dose is normal. Increasing early, against the schedule, is the fastest route to side effects severe enough to make you quit.

When to call your prescriber

Mild nausea, mild fatigue, and reduced appetite are expected and rarely require intervention beyond the eating adjustments above. Contact your provider promptly for severe or persistent vomiting, signs of dehydration, severe abdominal pain that radiates to your back, symptoms of gallbladder trouble, or any symptom that feels alarming. If nausea is tolerable but wearing, your prescriber can also hold you at your current dose longer before the next increase, or add a short course of anti-nausea medication — both are routine. The goal of the first month is not to push through misery but to find a sustainable rhythm, because these medications work over months and years — the STEP 4 trial (Rubino and colleagues, 2021) found that those who continued semaglutide kept losing weight while those switched to placebo regained much of it — and getting the opening weeks right is what makes that long run possible.